Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

Yetzugo is a long-acting HIV-1 capsid inhibitor that reduces the risk of sexually acquired HIV in adults and adolescents.

What kind of uptake can Gilead Sciences expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) ...

The US Food and Drug Administration (FDA) has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a ...

By Mariam Sunny and Mrinalika Roy (Reuters) -Shares of Gilead rose 3% after the U.S. Supreme Court on Friday upheld a federal ...

Labcorp (LH), and Gilead (GILD) rise as Supreme Court upholds right to free preventive care under Obamacare. Read more here.

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...

Approval of first twice-yearly HIV pre-exposure prophylaxis was based on results from the Phase III PURPOSE 1 and PURPOSE 2 ...

“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement.

The US Food and Drug Administration (FDA) has approved Gilead Sciences (Nasdaq: GILD) Yeztugo (lenacapavir) - the company’s ...

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over ...